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The TexRAD Cancer management technology is being used as a research tool in seven of 
the G8 Countries; FDA and CE approvals for clinical use are imminent. 
Project Summary 
Research to address the detection of weak structured signals from within highly variable 
cluttered imagery is being used to identify textural variations in Computed Tomography (CT) 
X-ray images of organ tissue. The technology has been spun out into a company, TexRAD Ltd, 
that was recently taken over by Feedback plc, an AIM listed stock-market company. TexRAD 
uses novel image processing technology as a means of detecting tissue abnormalities, typically 
cancer, assessing response to treatment, and predicting patients’ chances of survival. The 
detection process is being assessed via clinical research use in leading international Cancer 
research institutions using existing historical data in Europe, Asia and America. Regulatory 
approval for mainstream clinical use is imminent. Once regulatory approval has been gained 
TexRAD will be used for: cancer diagnosis, prognosis and treatment planning on current 
patients, which will save lives, generate a significant revenue stream and greatly increase the 
value of Feedback plc. TexRAD is Feedback’s only product. 
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Commercialisation 
One of the difficulties in creating products for medical application is the requirement for 
clinical trials, which are often prohibitively expensive. Our approach to this issue was to set up 
TexRAD Limited in order to sell our cancer diagnostic software to leading medical research 
laboratories. This has not only produced a revenue stream to support the company but has also 
resulted in the software being used in large independent clinical studies, which have been 
published in leading medical journals. This strategy has been very effective in enabling 
TexRAD  to apply for FDA and CE approvals based on clinical trials that are funded by the 
users of the software. This approach also has the effect of marketing TexRAD to an 
international audience. UK based research users include: University of Cambridge; Royal 
Marsden Hospital ; University College London Hospitals; Royal Surrey County Hospital; 
Kings College; Brighton & Sussex University Hospitals; Mount Vernon Hospital;  Velindre 
Cancer Centre. International research users include: John Hopkins University (36 Nobel 
Laureates, 14 in medicine) USA; Georgetown University Hospital USA; University of 
Mississippi USA; Massachusetts General Hospital USA; Scottdale  Clincal Research Institute 
USA; University of Wisconsin USA; Sunnybrook Health Sciences Centre Canada; Tata 
Memorial Hospital India; Aarhus University Hospital Denmark; European Institute of 
Oncology Milan; Olso University Hospitals Norway; University of Rome “Sapienza” Italy; 
Universitatsspital Basel Switzerland; The Evangelische Lungenklinik Berlin Germany; 
University of Tokyo at the Institute of Medical Science Japan; Centre Hospitalier Universitaire 
De Reims France; Seoul National University Bundang Hospital  Korea. As these institutions 
publish their results more research organisations are placing orders for the research version of 
the TexRAD software. Imaging Endpoints has purchased TexRAD; this US corporation works 
with some of the largest pharmaceutical and biotechnology companies conducting clinical trials 
and performing diagnostics on medical images. They are making extensive use of TexRAD  
for the assessment of CT images in connection with drug trials. A study will shortly be 
commenced of colorectal cancer patients (Stage IIIc) with either Regorafenib or Standard of 
Care (No Treatment) after adjuvant FOLFOX. The Sponsor is US Oncology Research and the 
Collaborator is Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma. 
Feedback plc has signed a research agreement with the Oxford Stone Group at the University 
of Oxford & Oxford University Hospital NHS Trust ("Oxford") in Oxford, UK to investigate 
the potential clinical application of Feedback's TexRAD texture analysis software on CT image 
data of patients with kidney stones. 
 
What the medical experts are saying about TexRAD: 
 
"TexRAD software has allowed us to predict survival outcomes in several different tumors and 
treatment situations in a research setting. The data acquisition process and analysis has been 
streamlined for large studies, and the applications and support by TexRAD software engineers 
and leaders has led to some amazing results" - Andrew D. Smith M.D. Ph.D., Director of 
Radiology Research, Body Radiologist and Oncologic Imager Assistant Professor, University 
of Mississippi Medical Center. 
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"TexRAD is a very powerful software analytical tool that allows for in-depth evaluation of solid 
tumors for predictive, prognostic and treatment response categorization. We have used it in 
our Core Imaging lab on multiple occasions to help accelerate drug development for our 
pharmaceutical clients. It truly offers advanced information unlike any other technology in the 
field!" - Ronald L Korn MD PhD, CEO and Founder Imaging Endpoints Core Lab, Arizona 
 
Dr. Ho-Young Lee, Assistant Professor in the Department of Nuclear Medicine, Seoul National 
University, College of Medicine, SNUBH  commented, "We are very excited with the prospects 
of using the TexRAD imaging research software platform in conjunction with the new  PET-
CT  scanner being installed at our institution, further reinforcing our vision and reputation of 
being early adopters of new technologies, particularly in the fascinating area of quantitative 
imaging and its applications in cancer care." 
 
The recent sale of TexRAD to South Korea as part of the new PET-CT scanner installed by 
Siemens at Seoul National University Bundang Hospital, (SNUBH) is significant as Seimens 
(one of the market leaders for scanning machines) are now starting to bundle TexRAD software 
into their equipment sales. 
 
The University has a significant shareholding in this company, at the time of writing its value 
was £4.1million. The value will increase greatly when FDA approval is obtained. 
 
The Award 
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